315 related articles for article (PubMed ID: 33691132)
1. Cancer immunotherapy: Macs in the middle.
Shoukry NH; Turcotte S
Immunity; 2021 Mar; 54(3):409-411. PubMed ID: 33691132
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
3. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
4. CD8
Wang W; Green M; Choi JE; Gijón M; Kennedy PD; Johnson JK; Liao P; Lang X; Kryczek I; Sell A; Xia H; Zhou J; Li G; Li J; Li W; Wei S; Vatan L; Zhang H; Szeliga W; Gu W; Liu R; Lawrence TS; Lamb C; Tanno Y; Cieslik M; Stone E; Georgiou G; Chan TA; Chinnaiyan A; Zou W
Nature; 2019 May; 569(7755):270-274. PubMed ID: 31043744
[TBL] [Abstract][Full Text] [Related]
5. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
6. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
7. CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy.
He QF; Xu Y; Li J; Huang ZM; Li XH; Wang X
Brief Funct Genomics; 2019 Mar; 18(2):99-106. PubMed ID: 29554204
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Terranova-Barberio M; Thomas S; Munster PN
Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
[TBL] [Abstract][Full Text] [Related]
9. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
10. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
12. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
[TBL] [Abstract][Full Text] [Related]
13. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy.
Jiang W; He Y; He W; Wu G; Zhou X; Sheng Q; Zhong W; Lu Y; Ding Y; Lu Q; Ye F; Hua H
Front Immunol; 2020; 11():622509. PubMed ID: 33633741
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
15. Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
Pilones KA; Hensler M; Daviaud C; Kraynak J; Fucikova J; Galluzzi L; Demaria S; Formenti SC
Oncoimmunology; 2020 Oct; 9(1):1830524. PubMed ID: 33150045
[TBL] [Abstract][Full Text] [Related]
16. Tissue-resident memory CD8
Wang T; Shen Y; Luyten S; Yang Y; Jiang X
Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8
Redmond WL; Linch SN
Hum Vaccin Immunother; 2016 Oct; 12(10):2519-2522. PubMed ID: 27459422
[TBL] [Abstract][Full Text] [Related]
18. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
19. CD8
Seo JW; Tavaré R; Mahakian LM; Silvestrini MT; Tam S; Ingham ES; Salazar FB; Borowsky AD; Wu AM; Ferrara KW
Clin Cancer Res; 2018 Oct; 24(20):4976-4987. PubMed ID: 29967252
[No Abstract] [Full Text] [Related]
20. Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy.
Zuazo M; Arasanz H; Bocanegra A; Fernandez G; Chocarro L; Vera R; Kochan G; Escors D
Front Immunol; 2020; 11():586907. PubMed ID: 33329566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]